$15 million funding signals growing demand for personalized obesity care that looks beyond medication alone.
What if the biggest challenge in obesity care isn’t finding effective treatments, but making sure people receive the right treatment at the right time? And what if the future of obesity medicine is about building a system that knows when medication, behavioral support, surgery, nutrition coaching or lifestyle changes are most likely to work for each individual?
These questions are becoming important as obesity rates continue to rise and demand for GLP-1 weight-loss medications accelerates. They are also at the core of Ilant Health’s latest funding announcement.
The New York-based obesity and cardiometabolic health company has raised $15 million in Series A financing, bringing its total funding to more than $22 million [1]. The round was led by Cornucopian Capital, with participation from naturalX, Peakbridge, Semcap AI, Evidenced, Operator Partners and existing investors Celtic, LifeX and AlphaLab.
While funding announcements have become commonplace in the obesity sector, Ilant’s story is a shift in healthcare from isolated interventions toward more coordinated, personalized care models designed to improve long-term outcomes.
Obesity treatment has often resembled a relay race where nobody passes the baton properly. A patient might receive a prescription from one provider, nutritional advice from another, behavioral support somewhere else and specialist care through an entirely different system. Each intervention may be valuable on its own, but the overall experience can feel fragmented. The result is that many people are left navigating a complex condition through a patchwork of disconnected services. Ilant believes that approach no longer makes sense.
Founded by Elina Onitskansky, whose background includes leadership roles at McKinsey and Molina Healthcare, the company works directly with employers and health plans to provide comprehensive obesity and cardiometabolic care. Rather than focusing on a single intervention, the model combines medical treatment, behavioral therapy, nutrition guidance, physical activity support and, where appropriate, bariatric surgery.
The goal is not simply to help people lose weight, but to create a care pathway that evolves as patients do.
Using AI to make care more adaptive
The company’s use of AI is about helping clinicians make better decisions over time, not replacing them. Most obesity care follows a relatively fixed route. Ilant’s platform continuously evaluates a person’s response to treatment and helps clinicians adjust the plan when necessary. If one approach is not delivering meaningful progress, another option can be introduced before valuable time is lost.
The company says treatment recommendations are informed by clinical, behavioral and personal data, allowing care to be matched more closely to individual needs. That personalization matters because obesity is rarely driven by a single factor. Biology, lifestyle, stress, environment and underlying health conditions can all play a role. A treatment strategy that works well for one person may prove ineffective for another.
Moreover, employers and health plans are increasingly under pressure to provide access to highly effective obesity medications while also managing rapidly rising healthcare costs. Recent demand for GLP-1 drugs has transformed the obesity market almost overnight. Yet access alone does not necessarily guarantee better outcomes, nor does it address the financial strain many organizations face.
“Employers and health plans are facing a real dilemma right now – they are faced with either expanding access and watching pharmaceutical costs rise dramatically, or restricting access and risking rising chronic disease and cost,” said Onitskansky.
Onitskansky asserted that the current healthcare model is unsustainable, warning that failing to alter how care is delivered would simply mean paying more for an already broken system. She cautioned that this inertia risks creating a crisis characterized by spiraling costs and chronic diseases. In contrast, she highlighted that Ilant’s model targets the delivery of genuine value by combining manageable treatment costs with clinically meaningful care that successfully bends the cost curve.
Early outcomes draw investor attention
According to Ilant, members enrolled in its programs have achieved an average weight loss of 15%, alongside improvements in broader health measures and overall wellbeing. The company also reports that participants experience an average of two additional mentally healthy days per month.
For investors, those figures are important because obesity rarely exists in isolation. It is closely linked to cardiovascular disease, diabetes and other chronic conditions that contribute significantly to healthcare spending and reduced quality of life.
“What stood out with Ilant was their precision-based, data-driven approach to obesity care, not a one-size-fits-all model centered on medication only,” said Kenneth L Gardner, Director of Growth, Benefit Operations, SEIU 775 Benefits Group.
Gardner explained that Ilant’s detailed analysis of their population successfully identified members who would see the greatest clinical and financial advantages, which gave the organization confidence in achieving both better health outcomes and a meaningful return on investment.
A longevity lesson beyond weight loss
The enthusiasm surrounding obesity medicine has largely centered on new drugs. However, as the market matures, investors appear increasingly interested in a different question: how do you turn short-term treatment success into lasting health? That is where companies like Ilant see an opportunity.
“We believe the next generation of category-defining companies will be those that deliver outcomes as a service, not just tools or access,” said Aryeh Ganz, Founder and Managing Partner of Cornucopian Capital.
The idea resonates well beyond obesity care. Across longevity and preventive medicine, there is growing recognition that lasting health rarely comes from a single intervention. The future is likely to belong to systems capable of continuously adapting to individual needs, monitoring progress and adjusting course over time – which brings us back to those opening questions.
Perhaps the future of obesity care is not about discovering one perfect solution. Perhaps it is about building a healthcare model that can keep learning alongside the people it serves.
If longevity is ultimately about helping people remain healthier for longer, then the real innovation may be the ability to deliver the right care, at the right moment, throughout an individual’s health journey.
